about
Nasal NK/T-Cell Lymphoma. A Comparative Analysis of a Mexican Population with the Other Populations of Latin-AmericaPrimary Esophageal Extranasal NK/T Cell Lymphoma With Biphasic Morphology: A Case Report and Literature ReviewDiagnosis and management of extranodal NK/T cell lymphoma nasal type.Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.Aggressive natural killer cell leukemia or extranodal NK/T cell lymphoma? a case with nasal involvement.Rare aggressive natural killer cell leukemia presented with bone marrow fibrosis - a diagnostic challenge.NK/T cell lymphoma with inverted papilloma: A rare coexistence.Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell lymphomaLong complete remission achieved with the combination therapy of Cisplatin and gemcitabine in a patient with aggressive natural killer cell leukemia.A TNM Staging System for Nasal NK/T-Cell Lymphoma.Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.How I treat the peripheral T-cell lymphomasFirst-line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: An updated analysis with long-term follow-upPrimary Intestinal Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Comprehensive Clinicopathological Analysis of 55 Cases.S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabineLong-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs.Primary Thyroid Extranasal NK/T-Cell Lymphoma Associated With Good Outcome: A Case Report and Literature Review: A Care-Compliant ArticleNasal Type Extranodal Natural Killer/T (NK/T) Cell Lymphoma Presenting as Periorbital Cellulitis: A Case Report.Utility of baseline, interim and end-of-treatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase.Extranodal natural killer/T-cell lymphoma presenting as cavernous sinus syndrome.Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications.Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin.Investigational drugs for T-cell lymphoma.Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era.The diagnosis and management of NK/T-cell lymphomas.Natural Killer Cell Lymphoma: A Case with Classification DilemmaL-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis.Extranodal NK/T-Cell Lymphoma, Nasal Type, Presenting as Refractory Pseudomonas aeruginosa Facial Cellulitis.The aggressive peripheral T-cell lymphomas: 2017.Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.CD56- extranodal natural killer (NK)/T-cell lymphoma, nasal type presenting as skin ulcers in a white manExome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.The first report of a previously undescribed EBV-negative NK-cell lymphoma of the GI tract presenting as chronic diarrhoea with eosinophilia.Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability.Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine.Uveitis and Myositis as Immune Complications in Chemorefractory NK/T-Cell Nasal-Type Lymphoma Successfully Treated with Allogeneic Stem-Cell Transplant.Evaluation of bone marrow involvement in extranodal NK/T cell lymphoma by FDG-PET/CT.Association between extranodal natural killer/T-cell lymphoma and hepatitis B viral infection: a case-control study.
P2860
Q26781684-91236E3C-6D94-478B-800F-A3689F99E97FQ26800228-0FFEB8C0-86F4-46F8-A4FF-E962D9C578D9Q30249309-710883D4-7B96-412E-9ED3-F46A17B3E538Q33415901-AE9EEB24-0ADE-476B-8EF2-F5E4AEC31817Q33423016-4CEE0B1D-B511-4C4E-A872-B3812ECD8FEAQ33433689-D36AAF03-1A7D-422C-A89B-D68D42B6F2AFQ33808534-5DAEA355-F3C0-44EC-9F0D-F1710EB735DFQ34037341-3FC6E33C-E405-4A82-9BB5-46AACCD40A28Q34146851-F2D8CB68-1BB7-4E05-A935-267C5EF2E7FDQ35044989-FC5CF477-4F0B-49A3-B87C-6C69B341031FQ35073901-C051A865-BFAA-4B21-87C6-07E48205EE61Q35670806-98F8888F-A4AB-4E4C-BF99-5F9FF869F031Q35713503-5A49140E-7FCE-4F76-84D6-9D0C8765FC64Q35865090-D08F5C02-004A-4C36-AB49-961CE5A013DBQ35871234-76970257-9905-441F-A9BC-912A834E17DBQ36114075-C8491F0F-90D7-46F0-A1EB-6A9F96A444EDQ36735918-31C4951F-B1AC-4D3F-A49A-4DCB3929EFA2Q36757012-05F31433-ABE5-4791-88C9-81E485492275Q36993044-141E7E2F-273A-4B1E-90EE-DDEF940154C1Q37496581-06ACC177-9328-48CE-A2B9-834AAC8FB5A2Q37602246-9AA59A31-28B9-4FE6-A4D2-30683CBCB7F8Q37732057-6B071611-6484-477B-B434-0E404586A0C9Q38289038-E8A99EDE-C3D4-4885-8B55-56DACF1FA7ACQ38418146-754C3469-C934-41F7-B31A-AEC223424B17Q38635909-6224D423-6ED0-4898-AB7F-370A0F9FCD9EQ39100902-1D20F221-1297-4735-B1F5-9E189D218B5FQ39243241-C2D4082D-B4BE-4B72-BAF3-6D80CC8A7CDAQ39245365-67BAB094-2FCE-4CF3-B29A-A2EB76A32318Q39377852-44DC21A8-3AD4-47E2-9096-708E30D8364EQ40106706-B5B9EF04-8178-4EA7-B4ED-BF0105DED405Q40197352-C8B10CF7-B9BF-4E65-8546-0A8301CC318BQ40441775-D7A9F5B3-B1C3-4D22-A197-9B6A5BF33304Q40535907-53F73BD3-FF09-464F-901B-0621E9186001Q40717160-28F09F54-8297-4D9F-BE3A-A584A9D9E84DQ40893172-CB1D02CC-4295-48F7-B695-90DAFDEFE5C2Q41001574-E331B3BC-F383-4270-A86B-58C72A58FDAAQ41541557-028D406F-04F1-43FB-A723-8583EFC87811Q41566224-E81C2F5F-C60A-4429-9D8E-9ED90B7775BEQ41641380-486DBFEC-0501-4C3A-B9DD-CDB4E6091E88Q41721837-BE8AEA34-254D-43B6-8575-7379B1ADAB0A
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
How I treat NK/T-cell lymphomas.
@ast
How I treat NK/T-cell lymphomas.
@en
How I treat NK/T-cell lymphomas.
@nl
type
label
How I treat NK/T-cell lymphomas.
@ast
How I treat NK/T-cell lymphomas.
@en
How I treat NK/T-cell lymphomas.
@nl
prefLabel
How I treat NK/T-cell lymphomas.
@ast
How I treat NK/T-cell lymphomas.
@en
How I treat NK/T-cell lymphomas.
@nl
P3181
P1433
P1476
How I treat NK/T-cell lymphomas.
@en
P304
P3181
P356
10.1182/BLOOD-2013-01-453233
P407
P577
2013-06-20T00:00:00Z